{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:52:56Z","timestamp":1760320376371},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Penile plication or partial excision with grafting has traditionally been the first-line treatment for stable Peyronie\u2019s disease (PD). Numerous injection therapies (ITs) have been introduced over the last few decades. Intralesional collagenase clostridium histolyticum (CCH) was U.S. Food and Drug Administration approved in 2013 for patients with stable disease, curvature \u226530\u00b0 and \u226490\u00b0, and intact erectile function. The impact of the advent of CCH on the surgical management of PD is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We studied the effect of IT on the surgical management of PD in a population-based analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Statewide Planning and Research Cooperative System database, which provides statewide level of all-payer data on patients in the outpatient, inpatient, ambulatory, and emergency department setting in New York State was reviewed. Patients undergoing a penile prosthesis for concurrent erectile dysfunction were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Descriptive statistics and multivariable logistic regression modeling were used to assess factors influencing choice of injection therapy vs surgical therapy (penile plication or partial excision with grafting).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 2003\u22122016, 547 patients with PD presented for management. Median age was 56 years and 57% were white. Over the study period, surgical management was used less often as the primary procedure with a concurrent increase in use of IT (P &amp;lt; .001). On multivariable modeling, patients more likely to receive IT as treatment for penile curvature were younger (odds ratio [OR]: 1.26; P = .002; CI: 1.09\u22121.46), of higher socioeconomic status (OR: 1.14; P = .037; CI: 1.01\u22121.29), presented in the post-CCH era (OR: 1.17; P = .018; CI: 1.03\u22121.33) and presented to a surgeon with a high volume practice (OR: 1.25; P = .007; CI: 1.07\u22121.48). Patients presenting in the post-CCH era were 17% significantly more likely to receive IT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>ITs like CCH are increasingly displacing surgical management as the primary treatment option of Peyronie\u2019s disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>The Statewide Planning and Research Cooperative System database is particularly useful for this analysis because it is an all-payer database that tracks patients longitudinally across various health care settings\u2014outpatient and inpatient. Limitations: It only includes patients in New York State limiting generalizability. The retrospective nature of the analysis makes it subject to the biases inherent in such reports. Specific disease level characteristics (eg, degree of curvature, duration of disease, and associated deformities) were not available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Since the introduction of CCH, there has been a markedly decreasing trend in the utilization of surgery as the primary modality in the management of PD-associated penile curvature.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.09.022","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T05:34:45Z","timestamp":1574314485000},"page":"111-116","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie\u2019s Disease: A Population-Based Analysis"],"prefix":"10.1093","volume":"17","author":[{"given":"Shyam","family":"Sukumar","sequence":"first","affiliation":[{"name":"Department of Urology , New York, NY , USA"},{"name":"Columbia University , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debduth Bardhan","family":"Pijush","sequence":"additional","affiliation":[{"name":"Department of Urology , New York, NY , USA"},{"name":"Department of Biostatistics , New York, NY , USA"},{"name":"Columbia University , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Brandes","sequence":"additional","affiliation":[{"name":"Chief , New York, NY , USA"},{"name":"Reconstructive Urology , New York, NY , USA"},{"name":"Given Foundation Professor of Urology , New York, NY , USA"},{"name":"Columbia University Medical Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"2023011111063850400_bib1","doi-asserted-by":"publisher","article-title":"A review of inflammation and fibrosis: Implications for the pathogenesis of Peyronie's disease. World J Urol","author":"Patel","DOI":"10.1007\/s00345-019-02815-6"},{"key":"2023011111063850400_bib2","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of peyronie's disease: Prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"2023011111063850400_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease: A review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","article-title":"Clinical efficacy of injection and mechanical therapy for Peyronie's disease: A systematic review of the literature","volume":"74","author":"Russo","year":"2018","journal-title":"Eur Urol"},{"key":"2023011111063850400_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's disease: AUA Guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J Urol"},{"key":"2023011111063850400_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"2023011111063850400_bib8","article-title":"Guidelines on penile curvature","author":"Hatzimouratidis"},{"key":"2023011111063850400_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"key":"2023011111063850400_bib10","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"2023011111063850400_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2023011111063850400_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: A phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib13","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1111\/jsm.12312","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib14","article-title":"Statewide Planning and Research Cooperative System (SPARCS)","author":"New York State Department of Health"},{"key":"2023011111063850400_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2023011111063850400_bib16","article-title":"Medical risk and comorbidity tools for ICD9-CM data. R package version 1.2","author":"McCormick"},{"key":"2023011111063850400_bib17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.05.027","article-title":"Radical prostatectomy sociodemographic disparities based on hospital and physician volume","author":"Omidele","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2023011111063850400_bib18","article-title":"Kendall rank correlation and Mann-Kendall trend test. R package version 2.2","author":"McLeod"},{"key":"2023011111063850400_bib19","article-title":"NEJM Journal Watch. First drug approved for Peyroni's disease","author":"Kelley"},{"key":"2023011111063850400_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.euf.2018.08.021","article-title":"Xiaflex for treatment of Peyronie's disease","volume":"4","author":"Shin","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2023011111063850400_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jsm.12721","article-title":"Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamasurg.2016.3605","article-title":"Treatment of dupuytren contracture with injectable collagenase within the Veterans Affairs System","volume":"152","author":"Duquette","year":"2017","journal-title":"JAMA Surg"},{"key":"2023011111063850400_bib23","first-page":"26","article-title":"Collagenase clostridium histolyticum is a cost-effective treatment for Peyronie\u2019s disease in appropriately selected patients","volume":"15","author":"Wymer","year":"2018","journal-title":"J Sex Med"},{"key":"2023011111063850400_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11552-014-9704-0","article-title":"Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren\u2019s contracture","volume":"10","author":"Muppavarapu","year":"2015","journal-title":"Hand (NY)"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/1\/111\/48526615\/jsm_17_1_111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/1\/111\/48526615\/jsm_17_1_111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:53:38Z","timestamp":1673448818000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/17\/1\/111\/6973698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,21]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.022","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie\u2019s Disease: A Population-Based Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}